View Financial HealthCogstate 配当と自社株買い配当金 基準チェック /26Cogstate配当を支払う会社であり、現在の利回りは0.71%で、収益によって十分にカバーされています。主要情報0.7%配当利回り0.7%バイバック利回り総株主利回り1.4%将来の配当利回り2.0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向21%最近の配当と自社株買いの更新お知らせ • Aug 23Cogstate Limited announces Annual dividend, payable on September 29, 2025Cogstate Limited announced Annual dividend of AUD 0.0200 per share payable on September 29, 2025, ex-date on August 27, 2025 and record date on August 28, 2025.すべての更新を表示Recent updatesお知らせ • 16hCogstate Limited to Report Fiscal Year 2026 Results on Aug 18, 2026Cogstate Limited announced that they will report fiscal year 2026 results at 4:12 PM, AUS Eastern Standard Time on Aug 18, 2026お知らせ • Jan 22Cogstate Limited Revises Earnings Guidance for the First Half Year Ended 31 December 2025Cogstate Limited revised earnings guidance for the first half year ended 31 December 2025. Total revenue $26.9 million, up 12% compared to previous corresponding period and above guidance of $25 million - $26 million.お知らせ • Jan 13Cogstate Limited to Report First Half, 2026 Results on Feb 19, 2026Cogstate Limited announced that they will report first half, 2026 results on Feb 19, 2026お知らせ • Aug 23Cogstate Limited announces Annual dividend, payable on September 29, 2025Cogstate Limited announced Annual dividend of AUD 0.0200 per share payable on September 29, 2025, ex-date on August 27, 2025 and record date on August 28, 2025.お知らせ • Aug 05Cogstate Limited, Annual General Meeting, Oct 16, 2025Cogstate Limited, Annual General Meeting, Oct 16, 2025.お知らせ • Jun 26Cogstate Limited Provides Earnings Guidance for the Second Half and Full Year Ending June 30, 2025Cogstate Limited provided earnings guidance for the second half and full year ending June 30, 2025. For the second half, the company expects revenues to be in the range of $28.1 million to $30.1 million, representing a material improvement on the first half of FY25. For the Full year, the company expects revenue is anticipated to be between $52 million and $54 million - an improvement of 20% to 24% on the prior year.お知らせ • May 29Cogstate Limited to Report Fiscal Year 2025 Results on Aug 22, 2025Cogstate Limited announced that they will report fiscal year 2025 results on Aug 22, 2025お知らせ • Jan 20Cogstate Limited to Report First Half, 2025 Results on Feb 20, 2025Cogstate Limited announced that they will report first half, 2025 results on Feb 20, 2025お知らせ • Oct 14Cogstate Appoints Kaycee Sink as Chief Medical OfficerCogstate announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies. Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial design decisions, endpoint selection, and data quality considerations for cognitive and clinical outcome assessments. Dr. Sink will also play a critical role in Cogstate’s efforts to commercialize cognitive assessment technologies within the community to support timely and more accurate diagnoses in healthcare. Dr. Sink joins Cogstate from Genentech (part of the Roche group of companies) where she was Principal Medical Director in Neurodegeneration, having leadership roles in the late-stage development of several molecules being studied for Alzheimer’s disease and other neurodegenerative disorders as well as digital applications for the same. She joined Genentech in 2017 after 13 years on faculty at Wake Forest School of Medicine, where she rose to tenured Full Professor of Medicine, Neurology, and Public Health Sciences. Dr. Sink is board certified in Internal Medicine and Geriatric Medicine with over 20 years of experience in clinical care and research in aging, Alzheimer’s disease, and other neurodegenerative disorders. She obtained her medical degree at the University of CA, San Francisco, and subsequently trained in internal medicine followed by clinical and research fellowships in geriatrics, also at UCSF. Dr. Sink continues to see patients and teach in the Memory Assessment Clinic as adjunct faculty at Wake Forest School of Medicine in Winston Salem, NC.お知らせ • Aug 24Cogstate Limited Provides Financial Guidance for the Fiscal Year 2025Cogstate Limited provided financial guidance for the fiscal year 2025. The company expects to grow revenue and profit in fiscal year 2025.お知らせ • Jan 15+ 2 more updatesCogstate Limited to Report First Half, 2024 Results on Feb 22, 2024Cogstate Limited announced that they will report first half, 2024 results on Feb 22, 2024お知らせ • Aug 23Cogstate Limited Provides Revenue Guidance for 2024Cogstate Limited provided revenue guidance for 2024. For the period, the company expects to grow revenue and profit.お知らせ • May 11Cogstate Limited Provides Revenue Guidance in the Fourth Quarter 2023Cogstate Limited provided earnings guidance for the he full year ended 30 June 2023. For the year, the company expects revenue to be in the range of $39 million - $41 million (9% - 12% below FY22); EBIT, from normal operations, is expected to be in the range of $1.0 million - $2.0 million; Net Profit before Tax, including restructure costs and interest revenue, is expected to be in the range of $0.6 million - $1.6 million.お知らせ • Feb 01+ 2 more updatesCogstate Limited to Report Fiscal Year 2023 Results on Aug 17, 2023Cogstate Limited announced that they will report fiscal year 2023 results on Aug 17, 2023お知らせ • Jan 25Cogstate Limited Announces Resignation of David Dolby as Non-Executive DirectorCogstate Limited advised that Mr. David Dolby has resigned as a non-executive director of Cogstate Ltd.決済の安定と成長配当データの取得安定した配当: COGZ.Fは配当の支払いを開始したばかりなので、配当金の支払いが安定しているかどうかを判断するのは時期尚早です。増加する配当: COGZ.Fは配当の支払いを開始したばかりなので、配当金が増加するかどうかを判断するのは時期尚早です。 配当利回り対市場Cogstate 配当利回り対市場COGZ.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (COGZ.F)0.7%市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Healthcare Services)1.2%アナリスト予想 (COGZ.F) (最長3年)2.0%注目すべき配当: COGZ.Fの配当金 ( 0.71% ) はUS市場の配当金支払者の下位 25% ( 1.42% ) と比べると目立ったものではありません。高配当: COGZ.Fの配当金 ( 0.71% ) はUS市場の配当金支払者の上位 25% ( 4.22% ) と比較すると低いです。株主への利益配当収益カバレッジ: COGZ.Fは低い 配当性向 ( 20.8% ) であるため、配当金の支払いは利益によって十分にカバーされます。株主配当金キャッシュフローカバレッジ: COGZ.Fは合理的な 現金配当性向 ( 64.6% ) を備えているため、配当金の支払いはキャッシュフローによって賄われます。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/09 20:54終値2026/06/09 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cogstate Limited 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Thomas WakimBell PotterElyse ShapiroCanaccord GenuityMadeleine WilliamsCanaccord Genuity2 その他のアナリストを表示
お知らせ • Aug 23Cogstate Limited announces Annual dividend, payable on September 29, 2025Cogstate Limited announced Annual dividend of AUD 0.0200 per share payable on September 29, 2025, ex-date on August 27, 2025 and record date on August 28, 2025.
お知らせ • 16hCogstate Limited to Report Fiscal Year 2026 Results on Aug 18, 2026Cogstate Limited announced that they will report fiscal year 2026 results at 4:12 PM, AUS Eastern Standard Time on Aug 18, 2026
お知らせ • Jan 22Cogstate Limited Revises Earnings Guidance for the First Half Year Ended 31 December 2025Cogstate Limited revised earnings guidance for the first half year ended 31 December 2025. Total revenue $26.9 million, up 12% compared to previous corresponding period and above guidance of $25 million - $26 million.
お知らせ • Jan 13Cogstate Limited to Report First Half, 2026 Results on Feb 19, 2026Cogstate Limited announced that they will report first half, 2026 results on Feb 19, 2026
お知らせ • Aug 23Cogstate Limited announces Annual dividend, payable on September 29, 2025Cogstate Limited announced Annual dividend of AUD 0.0200 per share payable on September 29, 2025, ex-date on August 27, 2025 and record date on August 28, 2025.
お知らせ • Aug 05Cogstate Limited, Annual General Meeting, Oct 16, 2025Cogstate Limited, Annual General Meeting, Oct 16, 2025.
お知らせ • Jun 26Cogstate Limited Provides Earnings Guidance for the Second Half and Full Year Ending June 30, 2025Cogstate Limited provided earnings guidance for the second half and full year ending June 30, 2025. For the second half, the company expects revenues to be in the range of $28.1 million to $30.1 million, representing a material improvement on the first half of FY25. For the Full year, the company expects revenue is anticipated to be between $52 million and $54 million - an improvement of 20% to 24% on the prior year.
お知らせ • May 29Cogstate Limited to Report Fiscal Year 2025 Results on Aug 22, 2025Cogstate Limited announced that they will report fiscal year 2025 results on Aug 22, 2025
お知らせ • Jan 20Cogstate Limited to Report First Half, 2025 Results on Feb 20, 2025Cogstate Limited announced that they will report first half, 2025 results on Feb 20, 2025
お知らせ • Oct 14Cogstate Appoints Kaycee Sink as Chief Medical OfficerCogstate announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies. Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial design decisions, endpoint selection, and data quality considerations for cognitive and clinical outcome assessments. Dr. Sink will also play a critical role in Cogstate’s efforts to commercialize cognitive assessment technologies within the community to support timely and more accurate diagnoses in healthcare. Dr. Sink joins Cogstate from Genentech (part of the Roche group of companies) where she was Principal Medical Director in Neurodegeneration, having leadership roles in the late-stage development of several molecules being studied for Alzheimer’s disease and other neurodegenerative disorders as well as digital applications for the same. She joined Genentech in 2017 after 13 years on faculty at Wake Forest School of Medicine, where she rose to tenured Full Professor of Medicine, Neurology, and Public Health Sciences. Dr. Sink is board certified in Internal Medicine and Geriatric Medicine with over 20 years of experience in clinical care and research in aging, Alzheimer’s disease, and other neurodegenerative disorders. She obtained her medical degree at the University of CA, San Francisco, and subsequently trained in internal medicine followed by clinical and research fellowships in geriatrics, also at UCSF. Dr. Sink continues to see patients and teach in the Memory Assessment Clinic as adjunct faculty at Wake Forest School of Medicine in Winston Salem, NC.
お知らせ • Aug 24Cogstate Limited Provides Financial Guidance for the Fiscal Year 2025Cogstate Limited provided financial guidance for the fiscal year 2025. The company expects to grow revenue and profit in fiscal year 2025.
お知らせ • Jan 15+ 2 more updatesCogstate Limited to Report First Half, 2024 Results on Feb 22, 2024Cogstate Limited announced that they will report first half, 2024 results on Feb 22, 2024
お知らせ • Aug 23Cogstate Limited Provides Revenue Guidance for 2024Cogstate Limited provided revenue guidance for 2024. For the period, the company expects to grow revenue and profit.
お知らせ • May 11Cogstate Limited Provides Revenue Guidance in the Fourth Quarter 2023Cogstate Limited provided earnings guidance for the he full year ended 30 June 2023. For the year, the company expects revenue to be in the range of $39 million - $41 million (9% - 12% below FY22); EBIT, from normal operations, is expected to be in the range of $1.0 million - $2.0 million; Net Profit before Tax, including restructure costs and interest revenue, is expected to be in the range of $0.6 million - $1.6 million.
お知らせ • Feb 01+ 2 more updatesCogstate Limited to Report Fiscal Year 2023 Results on Aug 17, 2023Cogstate Limited announced that they will report fiscal year 2023 results on Aug 17, 2023
お知らせ • Jan 25Cogstate Limited Announces Resignation of David Dolby as Non-Executive DirectorCogstate Limited advised that Mr. David Dolby has resigned as a non-executive director of Cogstate Ltd.